Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of PEG-Interferon Alpha-2b Regimens in Acute Hepatitis C
NCT00686517Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2003
- Primary completion
- Dec 2010
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
01
Overview
A Phase 3 trial of peginterferon alfa-2b in hepatitis C virus infection, sponsored by Merck & Co.. Started Dec 2003; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT00686517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00686517.